European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis
(World News Science)

August 15, 2019 European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis FOSTER CITY, Calif. & MECHELEN, Belgium--(BUSINESS WIRE)--Aug. 15, 2019-- Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults with rheumatoid arthritis (RA) has been validated and is now under evaluation by the European Medicines Agency (EMA). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190815005605/en/ `We are...